Sierra Internal Medicine
Sierra Internal Medicine is a clinic in Incline Village, Nevada, United States that treats ME/CFS patients, and takes part in research into ME/CFS.[1]
Ampligen[edit | edit source]
Sierra Internal Medicine, along with North Carolina's Hunter-Hopkins Center are the two primary clinics conducting clinical trials into Ampligen (rintatolimod) for severe ME/CFS. Ampligen is available under the compassionate use program.[1]
MCAM[edit | edit source]
Sierra Internal Medicine is also taking part in the CDC's Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or MCAM.[2][3]
Daniel Peterson[edit | edit source]
The 1984 Incline Village chronic fatigue syndrome outbreak affected many patients in the Incline Village area. Since that date, Dr Daniel L. Peterson, began specializing in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).[4][5][6] Dr Peterson continues to be a leader in ME/CFS treatment and research and serves on the Scientific Advisory Boards at Simmaron Research, the Faculty of Health Sciences and Medicine at Griffith University in Queensland, Australia, and the Open Medicine Foundation.[7][8] He has been based at Sierra Internal Medicine since 2010.[9]
Contact details[edit | edit source]
- Sierra Internal Medicine
- Incline Village
- Nevada
- United States 89451
- Phone: 775-831-4818
- Email: bbjorke@simmaron.com
See also[edit | edit source]
Learn more[edit | edit source]
- 2019, A Town for People with Chronic Fatigue Syndrome - New Yorker - about Ampligen
References[edit | edit source]
- ↑ 1.0 1.1 "Ampligen in Chronic Fatigue Syndrome". ClinicalTrials.gov. Retrieved August 13, 2018.
- ↑ Bateman, L.; Darakjy, S.; Klimas, N.; Peterson, D.; Levine, S.M.; Allen, A.; Carlson, S.A.; Balbin, E.G.; Gottschalk, G.; March, D. (2015). "Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study". Fatigue: Biomedicine, Health & Behavior. 3 (1): 1-15. doi:10.1080/21641846.2014.978109.
- ↑ Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017). "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study". American Journal of Epidemiology. 1–10. doi:10.1093/aje/kwx029.
- ↑ "Dr. Dan Peterson (Sierra Internal Medicine, Incline Village, Nevada) - Health Rising". Health Rising. Retrieved August 13, 2018.
- ↑ Strayer, DR; Carter, W; Strauss, KI; Brodsky, I; Suhadolnik, R; Ablashi, D; Henry, B; Mitchell, WM; Bastien, S; Peterson, D (1995). "Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen". Journal of Chronic Fatigue Syndrome. 1 (1): 35-53. doi:10.1300/J092v01n01_04.
- ↑ Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012). "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome". PLoS One. 7 (3): e31334. doi:10.1371/journal.pone.0031334. PMID 22431963.
- ↑ "Daniel L. Peterson, MD". Open Medicine Foundation. Retrieved April 1, 2019.
- ↑ "Collaborators - Simmaron Research". Simmaron Research. Retrieved August 13, 2018.
- ↑ "History of Changes for Study: NCT00215813 | Study of Ampligen in Chronic Fatigue Syndrome". ClinicalTrials.gov. April 8, 2010. Retrieved April 13, 2020.
